| Assessment Status | Company no longer intend to submit a full HTA dossier |
| HTA ID | 24050 |
| Drug | Spesolimab |
| Brand | Spevigo® |
| Indication | Spesolimab is indicated for the treatment of generalised pustular psoriasis (GPP) flares in adults and adolescents from 12 years of age as monotherapy. |
| Assessment Process | |
| Rapid review commissioned | 06/12/2024 |
| Rapid review completed | 19/12/2024 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of spesolimab compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 29/01/2025 |
| Pre-submission consultation with Applicant | 27/03/2025 |
The company has not submitted a HTA dossier to the NCPE; therefore the cost-effectiveness of the technology could not be proven.
